FDA approves AstraZeneca’s new treatment for people with asthma

AstraZeneca AZN UK:AZN said Wednesday that the Food and Drug Administration approved a new therapy that can be used to treat or prevent bronchoconstriction in adults with asthma. Thee company said Airsupra is a first-in-class treatment that is administered in an inhaler using a combination of albuterol and budesonide. U.S.-listed shares of AstraZeneca have gained 23.2% over the past 12 months, while the broader S&P 500 SPX is down 16.1%.

... AstraZeneca AZN AZN said Wednesday that the Food and Drug Administration approved a new therapy that can be used to treat or prevent bronchoconstriction in adults with asthma. Thee company said Airsupra is a first-in-class treatment that is administered in an inhaler using a combination of albuterol and budesonide. U.S.-listed shares of AstraZeneca have gained 23.2% over the past 12 months, while the broader S&P 500 SPX is down 16.1%.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA approves Alzheimer’s drug lecanemab amid safety concernsReports of deaths potentially linked to the treatment have cast a shadow on what many hail as a landmark approval. As a former AD researcher, it appears that these two new treatments offer no advantage over tacrine - approved in 1994 for AD. Its successor, donepazil, also had similar efficacy. Both were approved with large Phase 3 trials. But profits. Huge. Why are studies on on lipid medicines like gemfibrizol, sp, being ignored for new drugs with safety issues? It seems to have promising results blocking ab without any real problems as it's well tolerated and already prescribed thousands of times. I guess it doesn't pay as well...
Source: Nature - 🏆 64. / 68 Read more »